Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease

Phase 3Not Yet RecruitingNCT07658807

Xuanwu Hospital, Beijing300 enrolled

Overview

The goal of this clinical trial is to learn if adding a Traditional Chinese Medicine formula, Bu Yang Huanwu Decoction (specifically the capsule form called Hua Yu Wan Capsule), to standard treatment can help prevent leg pain at rest or foot ulcers in people with diabetic lower extremity vascular disease. The main questions it aims to answer are: Does adding Hua Yu Wan Capsule to standard treatment lower the chance of developing leg pain at rest or foot ulcers after one year, compared to standard treatment alone? Is the treatment combination safe for participants? Researchers will compare two groups: Group 1 (Experimental): Standard treatment (including aspirin, and medicines for blood sugar and cholesterol control) plus Hua Yu Wan Capsule. Group 2 (Control): Standard treatment alone. Participants in this study will: Be adults aged 18 to 70 years with diabetes and early to moderate lower extremity vascular disease (confirmed by tests like the Ankle-Brachial Index or ABI). Be randomly assigned to one of the two treatment groups. Take their assigned treatment for 6 months. Attend clinic visits at 1, 3 and 6 months during treatment, and again at 6 and 12 months after treatment ends for check-ups and tests.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

300

Conditions

Peripheral Arterial Disease Diabetic Angiopathies

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Aged 18 to 70 years (inclusive), male or female. 2. Diagnosed with diabetes mellitus according to the Chinese Diabetes Society (2024) Guidelines. 3. Glycated hemoglobin (HbA1c) \< 12%, with recent fasting blood glucose \< 7.0 mmol/L OR postprandial blood glucose \< 10.0 mmol/L, and triglycerides \< 1.7 mmol/L. 4. Diagnosed with LEAD, meeting the following criteria: Rutherford Classification 2, 3, or 4. Resting ABI ≤ 0.90, OR for patients with exertional symptoms and resting ABI \> 0.90, a post-exercise treadmill test showing an ABI decrease of ≥15%. Evidence of lower limb arterial stenosis or occlusion confirmed by duplex ultrasound, CTA, MRA, or DSA. 5. TCM Pattern Diagnosis: Must conform to the TCM syndrome of Qi Deficiency and Blood Stasis, as defined by the study's TCM diagnostic criteria (referencing "Practical Diagnostic Criteria for Blood Stasis Syndrome" and "Integrated Chinese and Western Medicine Peripheral Vascular Disease"): Main Symptom: Lower limb weakness, or feeling of heaviness/discomfort after prolonged walking. Secondary Symptoms: Shortness of breath/lassitude in speaking; dry mouth with desire to drink; scaly skin. Tongue \& Pulse: Tongue with teeth marks, pale-purple with petechiae/ecchymosis; thin and choppy pulse. (Diagnosis confirmed by meeting 1 main symptom OR 2 secondary symptoms, assessed by a qualified TCM practitioner.) 6. Voluntarily signs the Informed Consent Form (ICF) and is willing and able to comply with all study procedures and visits. Exclusion Criteria: 1. Known bleeding disorders or history of intracranial hemorrhage. 2. Current use of anticoagulants (e.g., warfarin, dabigatran, factor Xa inhibitors). 3. Presence of active infection. 4. Severe cardiac abnormalities on resting ECG (e.g., heart failure, ventricular tachycardia, ventricular fibrillation, multifocal ventricular contractions, prolonged corrected QT interval). 5. History of acute coronary syndrome ≤ 12 months requiring dual antiplatelet therapy. 6. Chronic liver disease (Child-Turcote-Pugh score ≥5) or chronic kidney disease stages 4-5 (eGFR \< 30 mL/min/1.73m²). 7. History of malignancy (except cured basal cell carcinoma). 8. Moderate to severe anemia, polycythemia vera, or any hyperviscosity syndrome. 9. Planned lower limb revascularization or amputation. 10. Concurrent or planned use of medicinal products containing Veratrum species. 11. Pregnant or lactating women, or women of childbearing potential not using highly effective contraception. 12. Known allergy or hypersensitivity to any component of the study medication (Qilong Capsules, aspirin). 13. Patients with psychiatric disorders or judged to be uncooperative. 14. Currently participating in another drug clinical trial or using therapies with similar purported effects. 15. Any other condition deemed by the investigator to make the participant unsuitable for the trial.

Outcomes

Primary Outcomes

Incidence of new-onset ischemic rest pain or foot ulcer at 12 months of treatment.

Ischemic Rest Pain: Persistent pain in the toes/forefoot at rest, typically nocturnal, worsened by elevation, relieved by dependency, often with pallor/coldness. Foot Ulcer: Ischemic skin breakdown/tissue necrosis in pressure areas (toes, heel, sole), with well-defined edges, dry/necrotic base, poor perfusion, and absence of significant inflammation. Assessment Method: Clinical evaluation by investigator at each scheduled visit. Confirmed by physical examination and documented photographically if applicable.

Time frame: From enrollment to the end of treatment at 12 months

Secondary Outcomes

Number of participants with investigator-confirmed new-onset ischemic rest pain or clinically confirmed ischemic foot ulcer at 12 months

Composite primary outcome defined as the number of participants who develop either: (1) new-onset ischemic rest pain confirmed by investigator clinical assessment, or (2) ischemic foot ulcer confirmed by physical examination with photographic documentation when applicable, by Month 12.

Time frame: From enrollment to the end of treatment at 12 months

Number of participants with major adverse cardiovascular and cerebrovascular events (MACCE)

MACCE is defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

Time frame: From enrollment to the end of treatment at 12 months

Number of participants hospitalized during the study

Number of participants who require inpatient hospitalization for any cause during the study period, as confirmed by hospital admission records or investigator documentation. Repeated hospitalizations in the same participant will be counted once unless otherwise specified in the statistical analysis plan.

Time frame: From enrollment to the end of treatment at 12 months

Number of participants who die during the study

Number of participants who die from any cause during the study period, as confirmed by medical records, death certificates, hospital documentation, or investigator follow-up. Each participant will be counted once.

Time frame: From enrollment to the end of treatment at 12 months

Change in ankle-brachial index（ABI） from baseline

Change in ankle-brachial index from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.

Time frame: reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18

Change in toe-brachial index (TBI) from baseline

Change in toe-brachial index from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.

Time frame: reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18

Change in intermittent claudication distance from baseline

Change in intermittent claudication distance from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.

Time frame: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18

Rate of clinically driven lower-extremity arterial revascularization after treatment

Rate of clinically driven lower-extremity arterial revascularization after treatment, including endovascular or open surgical revascularization: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.

Time frame: From enrollment to the end of treatment at 12 months

Change in Vascular Quality of Life Questionnaire-6 score from baseline

Change in Vascular Quality of Life Questionnaire-6 score from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.

Time frame: From enrollment to the end of treatment at 12 months

Change in Traditional Chinese Medicine syndrome score from baseline

Change in Traditional Chinese Medicine syndrome score from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.

Time frame: From enrollment to the end of treatment at 12 months

Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts